REG - IQ-AI Limited - Major East Coast Health System Chooses IB Nimble

IQ-AIAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5528Pa&default-theme=true

RNS Number : 5528P  IQ-AI Limited  23 May 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Major East Coast Health System Chooses IB Nimble for Their Brain Metastases
Program of Excellence

 

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE:
IQAI), today announces that a leading cancer centre located on the eastern
seaboard has subscribed to IB Nimble to optimize the care for patients with
metastatic brain cancer. IB Nimble is a handheld app, available on iOS and
Android devices and a web-based desktop version, that enables secure, remote,
and asynchronous discussions amongst multidisciplinary specialists.

 

Brain metastases occur when cancer cells spread to the brain from their
original site. This is common with breast, lung, and skin (melanoma) cancers.
Metastases are the most common type of brain cancer, and their prevalence is
increasing. This is due in part to the improved treatments for those other
cancers. As patients with these other cancers live longer, it is more likely
those cancer cells will eventually migrate to the brain.

 

The modern care of patients diagnosed with brain metastases requires expert
input from specialists in medical oncology, radiation oncology,
neuro-oncology, neurosurgery, and palliative care. This input is typically
obtained during weekly meetings or "tumor boards". Depending on when a patient
is admitted, they may need to wait multiple days until the tumor board meets
before a treatment plan can be developed.

 

Treatment decisions require timely discussions to provide optimal personalized
care. IB Nimble is integral to this effort as it facilitates real-time
discussion and collaboration amongst all the multidisciplinary specialists.
The mobile app will be used to improve the quality of care by, for example,
improving patient-reported outcomes, avoiding unnecessary hospital admissions,
and decreasing the length of hospital stays.

 

"The potential for multi-site collaboration is now literally in our hands with
IB Nimble," said Dr. Joe Bovi, MD, one of the inventors of IB Nimble. "We look
forward to working very closely with this health care centre," Dr. Bovi added.

 

"The product roadmap for IB Nimble is clear. By the end of 2024, our
development team will have completed significant enhancements to the software
architecture, including the addition of a highly requested feature - viewing
medical images," said Tim Dondlinger, COO of IB. "In advance of that, we are
already working on our sales pipeline," added Mr. Dondlinger.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUUSRRSSUVUUR